Pharmaceutical segment interim sales were 37,401 million yen (YoY -2.5%). While Tabneos sales declined, growth of Beova, Korsba, Tabalis, Ixelti and expanded co-promotion expenses helped maintain a certain sales mix. Overseas license income decreased. Overall sales fell short of initial forecasts. Operating income and ordinary income returned to profit, but interim net income attributable to owners of parent decreased due to special losses related to Tabneos.<\/p>\n","protected":false},"comment_status":"open","ping_status":"closed","template":"","meta":{"Ticker":"","DATE":"","longName":"","company_name_ja":"","fullTimeEmployees":0,"address":"","phone":"","website":"","industry":"","sector":"","regularMarketPrice":0,"financialCurrency":"","marketCap":0,"fiftyTwoWeekLow":0,"fiftyTwoWeekHigh":0,"epsTrailingTwelveMonths":0,"epsForward":0,"bookValue":0,"totalRevenue":0,"OperatingIncome":0,"operatingMargins":0,"NetIncome":0,"profitMargins":0,"ebitda":0,"trailingPE":0,"forwardPE":0,"priceToBook":0,"returnOnEquity":0,"recommendationMean":0,"recommendationKey":"","targetMeanPrice":0,"numberOfAnalystOpinions":0,"analyst_earnings_data":"","dividendRate":0,"dividendYield":0,"payoutRatio":0,"totalEsg":0,"environmentScore":0,"socialScore":0,"governanceScore":0,"title":"","providerPublishTime":"","link":"","longBusinessSummary":"","longBusinessSummary_ja":"","quarterly_revenue":0,"quarterly_net_income":0,"quarterly_operating_profit":0,"enterprise_value":0,"price_fetched_at":"","company_officer_1_name":"","company_officer_1_title":"","company_officer_2_name":"","company_officer_2_title":"","company_officer_3_name":"","company_officer_3_title":"","company_officer_4_name":"","company_officer_4_title":"","company_officer_5_name":"","company_officer_5_title":"","company_officers_update_time":"","get_dividend_history_year1":0,"get_dividend_history_year2":0,"get_dividend_history_year3":0,"get_dividend_history_year4":0,"get_dividend_history_year5":0,"get_dividend_history_year6":0,"get_dividend_history_year7":0,"get_dividend_history_year8":0,"get_dividend_history_year9":0,"get_dividend_history_year10":0,"site-sidebar-layout":"default","site-content-layout":"","ast-site-content-layout":"","site-content-style":"default","site-sidebar-style":"default","ast-global-header-display":"","ast-banner-title-visibility":"","ast-main-header-display":"","ast-hfb-above-header-display":"","ast-hfb-below-header-display":"","ast-hfb-mobile-header-display":"","site-post-title":"","ast-breadcrumbs-content":"","ast-featured-img":"","footer-sml-layout":"","theme-transparent-header-meta":"","adv-header-id-meta":"","stick-header-meta":"","header-above-stick-meta":"","header-main-stick-meta":"","header-below-stick-meta":"","astra-migrate-meta-layouts":"default","ast-page-background-enabled":"default","ast-page-background-meta":{"desktop":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"ast-content-background-meta":{"desktop":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"jir_stock_code":"4547","jir_company_name":"Kissei Pharmaceutical Co., Ltd.","jir_importance":"\u2605\u2605\u2605\u2605\u2606","jir_publication_date":"2026-11-04","jir_source_link":"https:\/\/japanir.jp\/wp-content\/uploads\/2026\/11\/4547-20261104-02.pdf","jir_short_summary":"Pharmaceutical segment interim sales were 37,401 million yen (YoY -2.5%). While Tabneos sales declined, growth of Beova, Korsba, Tabalis, Ixelti and expanded co-promotion expenses helped maintain a certain sales mix. Overseas license income decreased. Overall sales fell short of initial forecasts. Operating income and ordinary income returned to profit, but interim net income attributable to owners of parent decreased due to special losses related to Tabneos.","jir_summary":"### Overview of Results\nNet sales for the interim period were 45,503 million yen (YoY -0.7%), and the pharmaceutical segment recorded 37,401 million yen (YoY -2.5%), showing a slowdown. Flagship product Tabneos posted decreased sales, while products such as Beova, Korsba, Tabalis and Ixelti showed growth. Decreases in export and technical fee revenues also had an impact. On the profit side, operating income was 1,694 million yen and ordinary income was 2,923 million yen, maintaining a return to profitability; however, interim net income was 5,191 million yen, down year-on-year due to the recording of special losses. A decline in overseas license income also contributed.\n\n### Outlook and Key Points\nBased on interim results, full-year outlook remains cautious, but the progress of domestic and international new drug development and responses related to safety are expected to affect future profitability. The trajectory of new drugs such as Ixelti (original product), the market approval process for Tabneos, and development status of products for overseas launch are key points to watch.","jir_financial_highlights":"Net sales: 45,503 million yen (Quarter-on-Quarter -0.7%)\nPharmaceutical segment net sales: 37,401 million yen (Year-over-Year -2.5%)\nOperating income: 1,694 million yen (Compared with prior period -)\nInterim net income attributable to owners of parent: 5,191 million yen (Year-over-Year -27.4%)","jir_category":"","jir_hashtags":"#KisseiPharmaceutical, #Earnings, #Interim, #PharmaceuticalBusiness","jir_key_figures":"Net sales: 45,503 million yen\nPharmaceutical segment net sales: 37,401 million yen\nInterim net income attributable to owners of parent: 5,191 million yen","jir_meta_title":"Kissei Pharmaceutical Co., Ltd. - Key Points of Second Quarter Earnings | Fiscal Year Ending November 2026","jir_meta_description":"Summary of Kissei Pharmaceutical Co., Ltd.'s second quarter earnings. Sales were roughly flat year-on-year; the pharmaceutical business saw mixed growth and decline drivers. While profitability returned to black, interim net income decreased. New drug development and safety responses are focal points going forward.","jir_og_title":"Kissei Pharmaceutical Co., Ltd. - Key Points of Second Quarter Earnings | Fiscal Year Ending November 2026","jir_og_description":"Summary of Kissei Pharmaceutical Co., Ltd.'s second quarter earnings. Sales were largely flat, with mixed contributions from key products. Profitability returned to positive territory, though special losses had an impact.","jir_og_image_url":"\/assets\/og\/company-general_ir.jpg","jir_chart_data_collection":"[]","ir_related_company":8930,"ir_release_date":"","ir_type":"","ir_is_new":false,"ir_document_url":"","jir_ir_type":"financial_summary","footnotes":""},"sector":[],"importance":[],"class_list":["post-141386","ir_release","type-ir_release","status-publish","hentry"],"yoast_head":"\n